Group 1: AI in Healthcare - Morgan Stanley's healthcare conference highlighted a partnership between Nvidia and Eli Lilly, investing $1 billion over five years to establish a joint research lab in the San Francisco Bay Area to accelerate AI drug development [1] - OpenAI launched ChatGPT Health, allowing users to securely connect medical records and health applications to an AI chatbot for health consultations and data interpretation [1] - Ant Group's AI health assistant "Ant Aifu" gained significant user attention by linking multiple hospitals and real doctors for health consultations and medical services [1] Group 2: Market Trends and Insights - CITIC Securities reported that by 2026, AI healthcare payment sources will become clearer and more robust, enhancing the commercial viability of AI in healthcare and accelerating the restructuring of the pharmaceutical market [2] - Aijian Securities noted rapid development in AI healthcare across policy, technology, products, and application scenarios, with future applications expected to extend from tertiary hospitals to grassroots terminals and individual users [2] - Guojin Securities emphasized that the Morgan Stanley healthcare summit serves as a global investment barometer, with several Chinese companies planning presentations that could boost expectations for innovative drug business development [2] Group 3: AI Medical Companies - Runta Medical launched a large model-based interpretation system for complex report analysis, assisting doctors in decision-making, and is developing automated pre-processing robots and logistics AGVs for sample handling [2] - Anbiping focuses on pathology diagnosis with digital pathology AI that can automatically identify cancerous areas and generate structured reports, while also developing automated slide scanning and staining robots [3] - United Imaging leverages AI in high-end medical imaging equipment, with an AI-assisted diagnostic system that can mark lesions in CT and MRI scans in real-time [3] Group 4: AI Drug Development - Hongbo Pharmaceutical has developed an AI drug design platform that supports new drug projects through CADD/AIDD technologies [4] - Chengdu XianDao is building a closed-loop R&D platform integrating a trillion-level small molecule compound library with AI and automation [4] - Hanyu Pharmaceutical collaborates with Huawei to develop a large model for peptide and oligonucleotide drug research, utilizing AI for molecular design and virtual screening [4] Group 5: CRO/CMO Services - WuXi AppTec operates as a fully integrated biopharmaceutical service platform, covering chemical drugs and cell gene therapies with global operational presence [5] - Zhaoyan New Drug focuses on preclinical CRO services, emphasizing safety evaluations and participating in clinical evaluations for stem cell and CAR-T cell therapies [5] - Tigermed provides full-process clinical trial services, with its subsidiary developing an AI model platform for new drug research and clinical trial support [6]

中邮证券发布研报称，2026年初政策支持与海外AI医疗公司高增长表现，共同催化"AI+医疗"产业机 遇。据预测，2030年全球市场规模有望达1553亿美元，中国将快速增长至168亿美元。AI在制药、医疗 影像、辅助诊疗等领域正步入成熟应用，推动产业链价值提升，医疗AI三类证审批加速进一步助力行 业持续扩张。 中邮证券主要观点如下： 政策及板块热点共振，"AI+医疗"有望迎来加速 政策面：2026年1月7日，国家工业和信息化部等八部门联合印发了《"人工智能+制造"专项行动实施意 见》提出要"推动智能装备迭代"，重点提及AI在高端医疗装备、远程医疗等场景应用，相关领域有望显 著受益于政策驱动。 "AI+医疗"市场有望超千亿美元，板块享受估值溢价 市场空间方面，"AI+医疗"行业人工智能解决方案的全球市场规模预计将由2022年的137亿美元增至 2030年的1553亿美元，CAGR为35.5%，中国市场至2030年有望达到168.3亿美元，行业存在爆发式增长 机会。在国内政策导向下，医疗AI三类证审批加速，截至2025年12月5日，累计已有207款人工智能医 疗器械获三类医疗器械注册证，其中，2025年以来新增获批 ...

Core Viewpoint - The AI healthcare sector in Hong Kong is experiencing a strong bullish trend, driven by clear industry trends and significant market demand for AI health solutions [1] Group 1: Market Performance - Alibaba Health has surged over 13%, leading the market with a cumulative increase of over 46% this month [1] - Other notable performers include Yidu Tech with a rise of over 9%, MicroPort Robotics up by 8.9%, and Ping An Good Doctor increasing by over 4% [1] - Additional companies such as Yimaitong, JD Health, and Gushengtang also saw gains [1] Group 2: Industry Drivers - The launch of Ant Group's AI health assistant "Antifufu" has seen monthly active users exceed 30 million, with daily inquiries surpassing 10 million, indicating strong demand in the health AI sector [1] - OpenAI's introduction of "ChatGPT Health" on January 8 further emphasizes the confidence of leading AI companies in the health AI market [1] Group 3: Market Forecast - Frost & Sullivan predicts that China's "AI + healthcare" market will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% over the next decade [1] - Huafu Securities reports that the AI healthcare industry is entering a critical phase of commercialization, supported by national strategies and market demand [1] - The report highlights a closed-loop demand for AI applications, which will sustain the continuous development of the AI industry [1]

Core Viewpoint - The recent surge in Hong Kong's AI healthcare stocks is driven by a clear confirmation of industry trends, with significant growth in user engagement and market potential for AI applications in healthcare [1][3][6] Group 1: Stock Performance - Alibaba Health has seen a rise of over 15%, with a cumulative increase of over 49% in January [1][6] - Other notable performers include Yidu Tech (up over 9%), MicroPort (up over 8%), Ping An Good Doctor (up over 5%), and JD Health (up over 2%) [1][6] Group 2: Market Analysis - The launch of Ant Group's AI health assistant "Antifufu" has resulted in over 30 million monthly active users and over 10 million daily inquiries, indicating strong demand in the health AI sector [3][8] - OpenAI's introduction of "ChatGPT Health" further emphasizes the confidence of leading AI companies in the health AI market [3][8] Group 3: Market Forecast - Frost & Sullivan predicts that China's "AI + healthcare" market will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% over the next decade [3][8] - Huafu Securities reports that the AI healthcare industry is entering a critical phase of commercialization, supported by national strategies and market demand [3][8] Group 4: Industry Innovation - Huachuang Securities anticipates that advancements in AI model capabilities will lead to comprehensive integration of AI in the healthcare industry, driving technological innovation [3][8] - The reduction in computing costs is expected to accelerate investments in AI capabilities by leading companies in various healthcare segments, potentially leading to a period of robust industry growth [3][8]

Core Viewpoint - The AI healthcare sector is experiencing significant growth, with both A-shares and Hong Kong stocks showing strong performance, particularly in AI medical ETFs and related stocks [1][2][3] Group 1: A-share Market Performance - The largest medical ETF in the A-share market (512170) surged by 3%, reaching a near three-month high, with active trading exceeding 1 billion CNY within the first hour of trading [1] - Key stocks such as Meiyuan Health and Weining Health saw substantial gains, with Meiyuan Health achieving a four-day consecutive rise and Weining Health spiking by 14% at one point [1] Group 2: Hong Kong Market Performance - The Hong Kong medical sector continues to strengthen, with the Hong Kong Stock Connect medical theme index rising consistently since the beginning of the year, led by Alibaba Health, which increased by nearly 10% [2] - The newly listed Hong Kong Stock Connect medical ETF (159137) has seen significant gains, with a trading volume exceeding 110 million CNY and a peak increase of nearly 3% within three days of its launch [2] Group 3: AI Healthcare Developments - Recent collaborations in the AI healthcare field include a partnership between NVIDIA and Eli Lilly to invest 1 billion USD over five years in an AI drug development lab in Silicon Valley [3] - In China, Tsinghua University's team has developed an AI-driven high-throughput drug virtual screening platform, DrugCLIP, with research results published in the journal Science [3] - The penetration rate of AI healthcare applications is rapidly increasing, with Ant Group's AI assistant, Antifufu, surpassing 30 million monthly active users, and OpenAI's ChatGPT Health reaching over 40 million daily users globally [3] Group 4: Brain-Computer Interface Developments - Elon Musk announced that Neuralink's brain-computer interface products are set to enter mass production by 2026, with nearly automated surgical procedures [3] - Strong Brain Technology, a leading domestic company in the brain-computer interface sector, has submitted an IPO application to the Hong Kong Stock Exchange [3] - The Ministry of Industry and Information Technology in China has indicated a focus on quantum technology and brain-computer interfaces during the 14th Five-Year Plan, emphasizing technological breakthroughs and enterprise cultivation [3]

行业相对指数表现（相对值） 强于大市 |维持 行业基本情况 | | 收盘点位 | 8787.25 | | --- | --- | --- | | 52 | 周最高 | 9323.49 | | 52 | 周最低 | 6790.4 | 2025-01 2025-03 2025-06 2025-08 2025-10 2026-01 -4% 0% 4% 8% 12% 16% 20% 24% 28% 32% 36% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 证券研究报告：医药生物|点评报告 行业投资评级 l AI 在制药、辅助诊断、医疗服务等领域步入成熟阶段 在制药领域，凭借 AI 技术平台强大的数据分析和模型预测能力， 相关公司在分子设计和药物筛选方面能够大幅提升药物的研发效率 和成功率。AI 制药公司通过和大型药企合作共同推动管线进展，涉及 计算机、物理、化学、生物、临床等交叉领域，管线推进越靠后，价 值量显著增高。在影像/手术领域：AI 通过在医疗影像分析方向深度 学习，能够快速识别病灶，实现精准诊断；AI 亦能辅助术前及术中及 时规划，并提供综合解决方案。在辅助诊断领域，主要参与者为数据 驱动型平台 ...

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 9%, currently trading at 7 HKD with a transaction volume of 185 million HKD, following the announcement of winning the first prize in the Shaanxi division of the 8th Smart Medical Innovation Competition for a project in collaboration with Xi'an Jiaotong University Second Affiliated Hospital [1][1][1] Group 1: Awards and Recognition - Yidu Technology has won over 20 awards in national industry competitions, showcasing the company's strong capabilities in AI-driven medical innovation [1][1] - The recent award reflects the practical implementation of Yidu Technology's strategy of "AI-driven medical innovation" [1] Group 2: AI Product and Solutions - As a leading company in the AI medical field, Yidu Technology has established a comprehensive AI product and solution system covering the entire healthcare industry chain, including medicine, insurance, and patient care [1][1] - By September 30, 2025, YiduCore, the company's AI medical intelligence platform, is expected to have processed and analyzed nearly 7 billion authorized medical records, with a network of over 10,000 hospital collaborations [1][1] - The company's intelligent solutions support various scenarios in hospital diagnosis, research, and operational management, contributing to the high-quality development and research innovation of numerous hospitals [1]

Group 1 - The A-share and Hong Kong stock markets are experiencing a surge in AI healthcare stocks, with the largest medical ETF (512170) reaching a 3% increase, marking a three-month high [1][7] - Major AI healthcare stocks such as Meinian Health have achieved four consecutive trading limits, while Weining Health saw a spike of 14% [1][7] - The trading volume for the medical ETF (512170) exceeded 1 billion CNY within the first hour of trading [1][7] Group 2 - The Hong Kong medical sector continues to strengthen, with the Hong Kong Stock Connect medical theme index rising consistently since the beginning of the year, led by Alibaba Health with nearly a 10% increase [1][9] - The newly listed Hong Kong Stock Connect medical ETF (159137) has seen significant gains, with a trading volume surpassing 110 million CNY within three days of its launch [1][9] Group 3 - Recent developments in AI healthcare include a partnership between NVIDIA and Eli Lilly to invest 1 billion USD over five years in an AI drug research lab in Silicon Valley [2][10] - Tsinghua University has developed an AI-driven high-throughput drug virtual screening platform, DrugCLIP, with results published in the journal Science [2][10] - The penetration rate of AI healthcare in the consumer sector is rapidly increasing, with Ant Group's AI assistant user base exceeding 30 million monthly active users [2][10] Group 4 - In the brain-computer interface sector, Elon Musk announced that Neuralink's products will enter mass production by 2026, with nearly automated surgical operations [3][10] - Strong Brain Technology, a leading domestic company in brain-computer interfaces, has reportedly submitted an IPO application to the Hong Kong Stock Exchange [3][10] - The Ministry of Industry and Information Technology has indicated a focus on quantum technology and brain-computer interfaces during the 14th Five-Year Plan, emphasizing technological advancements and enterprise cultivation [3][10]

Core Viewpoint - Yidu Technology (02158) has seen its stock price increase by over 9%, currently trading at 7 HKD with a transaction volume of 185 million HKD, following the announcement of winning the first prize in the Shaanxi division of the 8th Smart Medical Innovation Competition for a project in collaboration with Xi'an Jiaotong University Second Affiliated Hospital [1] Group 1: Company Achievements - Yidu Technology has won over 20 awards in national industry competitions, showcasing its strong capabilities in AI-driven medical innovation [1] - The company has established a comprehensive AI product and solution system covering the entire healthcare industry chain, including medicine, insurance, and patient care [1] Group 2: Project and Technology Impact - The project "Fusion Innovation New Quality Productivity to Support High-Quality Development of Smart Breast Disease Discipline" reflects the company's strategic focus on AI-driven medical innovation [1] - As of September 30, 2025, YiduCore, the company's AI medical intelligence platform, has processed nearly 7 billion authorized medical records and has a cooperative network of over 10,000 hospitals [1] - The company's intelligent solutions support various scenarios in hospital diagnosis, research, and operational management, contributing to the high-quality development and research innovation of numerous hospitals [1]

Market Performance - The three major indices collectively rose after a slight increase, with the Shanghai Composite Index down by 0.64%, the Shenzhen Component down by 1.37%, and the ChiNext Index down by 1.96% [1] - Over 3,700 stocks declined in the two markets, with a total trading volume of 3.65 trillion [1] Aerospace and Defense Sector - The aerospace sector opened low and continued to decline, closing down by 6.75%, with over 10 stocks, including Aerospace Huanyu and Guanglian Aviation, hitting the daily limit down or falling over 10% [3] - More than 20 industry sectors, including commercial aerospace, large aircraft, satellite internet, controllable nuclear fusion, military-civilian integration, aircraft carrier concepts, and space station concepts, experienced declines of over 4% [3] AI and Healthcare Sector - The AI application concept rose against the trend, with over 10 stocks, including Gravity Media and Lioo Co., hitting the daily limit up [3] - The AI healthcare concept remained active, with Meiyan Health achieving three consecutive limit ups, and stocks like Hongbo Pharmaceutical and Xin Ganjiang also hitting the daily limit up [3] Market Dynamics - Today's market pullback was anticipated, as the trading volume continued to increase significantly while the main funds were flowing out [3] - Compared to the previous day's trading volume of 3.15 trillion, today's volume increased by 49.6 billion, with a net outflow of main funds reaching 141.165 billion [3]